PLEOPHARMA TO PRESENT NEWDATA ON CANNABIS WITHDRAWAL In PATIENTS WITH CANNABIS USE DISORDER AND PHASE 2 PP-01 RESULTS AT THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE 88TH ANNUAL SCIENTIFIC MEETING

Presentations will highlight the patient experience of cannabis withdrawal/cannabis use disorder and Phase 2 CAN-002 data for investigational PP-01 in adults with cannabis use disorderPHOENIXVILLE, Pa., June 15, 2026 /PRNewswire/ — PleoPharma, a clinical-stage clinical development company focused on…

Read the full release →

News provided by PR Newswire.